Trial
NCT00632827
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of California, San Francisco
Collaborators
Eisai Inc.; Washington University School of Medicine
Condition
Peripheral T-Cell Lymphoma
Intervention
Gemcitabine
Why stopped
Manufacturing shortage of both Diftitox and Doxil
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-27